Search results for "Antitumor"

showing 10 items of 520 documents

Diorganotin(IV) N-acetyl-L-cysteinate complexes: synthesis, solid state, solution phase, DFT and biological investigations.

2009

Diorganotin(IV) complexes of N-acetyl-L-cysteine (H(2)NAC; (R)-2-acetamido-3-sulfanylpropanoic acid) have been synthesized and their solid and solution-phase structural configurations investigated by FTIR, Mössbauer, (1)H, (13)C and (119)Sn NMR spectroscopy. FTIR results suggested that in R(2)Sn(IV)NAC (R = Me, Bu, Ph) complexes NAC(2-) behaves as dianionic tridentate ligand coordinating the tin(IV) atom, through ester-type carboxylate, acetate carbonyl oxygen atom and the deprotonated thiolate group. From (119)Sn Mössbauer spectroscopy it could be inferred that the tin atom is pentacoordinated, with equatorial R(2)Sn(IV) trigonal bipyramidal configuration. In DMSO-d(6) solution, NMR spectr…

Binding SitesMolecular StructureLigandStereochemistryCell SurvivalSpectrum Analysischemistry.chemical_elementAntineoplastic AgentsNuclear magnetic resonance spectroscopyBiochemistryMedicinal chemistryAcetylcysteineCell LineInorganic Chemistrychemistry.chemical_compoundTrigonal bipyramidal molecular geometryDeprotonationchemistryMössbauer spectroscopyOrganotin CompoundsOrganotin(IV) FTIR Mössbauer NMR DFT Antitumor activityHumansDensity functional theoryCarboxylateTinJournal of inorganic biochemistry
researchProduct

Reactivity of anticancer metallodrugs with serum proteins: New insights from size exclusion chromatography-ICP-MS and ESI-MS

2010

International audience; A method based on the coupling of high resolution size-exclusion liquid chromatography using a polymer stationary phase with inductively coupled plasma mass spectrometry was developed to study the interactions of two metallodrugs - cisplatin and RAPTA-T - with the serum proteins albumin and transferrin. In contrast to previous approaches, the technique allowed the total recovery of the metals from the column and was able to discriminate between the different species of the metallodrugs and their complexes with the proteins at femtomolar detection levels. Metal binding was found to be dependent on the protein concentration and on the incubation time of the sample. Cis…

Binding-SitesElectrospray ionizationSize-exclusion chromatographyPeptidePlasma-Mass Spectrometry010402 general chemistry01 natural sciencesArticleAnalytical ChemistryOrganometallic Ruthenium CompoundCapillary electrophoresisComplexes[CHIM.ANAL]Chemical Sciences/Analytical chemistry[CHIM]Chemical SciencesInductively coupled plasma mass spectrometrySpectroscopychemistry.chemical_classificationChromatographyChemistry010401 analytical chemistryCisplatin BindingTransferrinAlbuminCapillary-ElectrophoresisMultidimensional Liquid-ChromatographyBlood proteins0104 chemical sciencesTransferrinPlatinum Antitumor ChemistryEscherichia-Coli
researchProduct

PEG-benzofulvene copolymer hydrogels for antibody delivery.

2010

A new amphiphilic copolymer have been synthesized starting from the hydrosoluble polyaspartylhydrazide (PAHy) polymer, by grafting both hydrophilic PEG(2000) chains and hydrophobic palmitic acid (C(16)) moieties on polymer backbone, and the structure of obtained PAHy-PEG(2000)-C(16) copolymer have been characterized by 2D (1)H/(13)C NMR experiments. PAHy-PEG(2000)-C(16) copolymer showed the ability of self-assembling in aqueous media giving a core-shell structure and resulted potentially useful for encapsulating and dissolving hydrophobic drug. The formation of micellar core-shell structure has been investigated by 2D (1)H NMR NOESY experiments. The presence of cross-peaks for protons of C(…

BiocompatibilityCell SurvivalPolymersSurface PropertiesPEG-benzofulvene immunoglobulin delivery hydrogelsimmunoglobulinsPharmaceutical SciencePolyethylene Glycolschemistry.chemical_compoundDrug Delivery SystemsCell Line TumorPolymer chemistryPEG ratioCopolymerHumansantibody deliverybenzofulvene copolymerschemistry.chemical_classificationChemistrytechnology industry and agricultureHydrogelsantibody delivery; benzofulvene copolymers; hydrogels; immunoglobulinsPolymerMacromonomerIndenesSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoImmunoglobulin GDrug deliverySelf-healing hydrogelsbenzofulvene copolymerhydrogelDrug Screening Assays AntitumorRheologyEthylene glycolInternational journal of pharmaceutics
researchProduct

Synthesis of 131I-labeled glucose-conjugated inhibitors of O6-methylguanine-DNA methyltransferase (MGMT) and comparison with nonconjugated inhibitors…

2006

O 6 -Substituted guanine derivatives are powerful agents used for tumor cell sensitization by inhibition of the DNA repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT). To provide targeted accumulation of MGMT inhibitors in tumor tissue as well as tools for in vivo imaging, we synthesized iodinated C 8 -alkyl-linked glucose conjugates of 2-amino-6-(5-iodothenyl)-9H-purine (O 6 -(5-iodothenyl) guanine, ITG) and 2-amino-6-(3-iodobenzyloxy)-9H-purine (O 6 -(5-iodobenzyl) guanine, IBG). These compounds have MGMT inhibitor constants (IC 5 0 values) of 0.8 and 0.45 μM for ITGG and IBGG, respectively, as determined in HeLa S3 cells after 2-h incubation with inhibitor. To substantiate tha…

BiodistributionMethyltransferaseGuanineTime FactorsDNA repairGuanineTransplantation HeterologousMice NudeAntineoplastic AgentsIn Vitro Techniqueschemistry.chemical_compoundMiceO(6)-Methylguanine-DNA MethyltransferaseStructure-Activity RelationshipIn vivoIodine IsotopesDrug DiscoveryAnimalsHumansEnzyme Inhibitorschemistry.chemical_classificationbiologyMolecular StructureXenograft Model Antitumor AssaysEnzymeGlucosechemistryBiochemistryEnzyme inhibitorbiology.proteinMolecular MedicineEx vivoHeLa CellsJournal of medicinal chemistry
researchProduct

Polyaspartamide-Doxorubicin Conjugate as Potential Prodrug for Anticancer Therapy

2015

Purpose To synthesize a new polymeric prodrug based on ?,?- poly(N-2-hydroxyethyl)(2-aminoethylcarbamate)-d,l-aspartamide copolymer bearing amine groups in the side chain (PHEA-EDA), covalently linked to the anticancer drug doxorubicin and to test its potential application in anticancer therapy. Methods The drug was previously derivatized with a biocompatible and hydrophilic linker, leading to a doxorubicin derivative highly reactive with amino groups of PHEA-EDA. The PHEAEDA- DOXO prodrug was characterized in terms of chemical stability. The pharmacokinetics, biodistribution and cytotoxicity of the product was investigated in vitro and in vivo on human breast cancer MCF-7 and T47D cell lin…

BiodistributionPolymeric prodrugPharmaceutical ScienceBreast NeoplasmsMice SCIDpolymeric prodrugPharmacologyMice Inbred NODCell Line TumorPolyaminesmedicineSide chainAnimalsHumansProdrugsTissue Distributionantitumor activityDoxorubicinPharmacology (medical)BreastAspartamebiodistributionPharmacologyChemistryPHEA-EDAOrganic ChemistryProdrugAnticancer drugPolyaspartamideDoxorubicinMCF-7 CellsMolecular MedicineFemaleAmine gas treatingantitumor activity; biodistribution; doxorubicin; PHEA-EDA; polymeric prodruganti-cancer therapymedicine.drugConjugateBiotechnology
researchProduct

Recent developments and applications of smart nanoparticles in biomedicine

2022

Abstract Over the last decades, nanotechnology applied in medicine (nanomedicine) has sparked great interest from the scientific community, thanks to the possibility to engineer nanostructured materials, including nanoparticles (NPs), for a specific application. Their small size confers them unique properties because they are subject to physical laws in the middle between classical and quantum physics. This review is proposed to explain better how to design a specific NP and clarify the relationship between the type, size, and shape of NPs and the specific medical applications. NPs are classified into inorganic (metallic NPs, quantum dots, carbon-based nanostructures, mesoporous silica NPs)…

Biomaterialsantimicrobial techniquetissue engineeringProcess Chemistry and Technologydrug deliveryorganic and inorganic nanoparticleEnergy Engineering and Power TechnologyMedicine (miscellaneous)bioimagingantitumor therapynanovaccinesSurfaces Coatings and FilmsBiotechnologyNanotechnology Reviews
researchProduct

Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.

2001

One of the best known bioactive triterpenoids is oleanolic acid, a widespread 3-hydroxy-17-carboxy oleanane-type compound. In order to determine whether further oxidation of carbon 3 affects anti-inflammatory activity in mice, different tests were carried out on oleanolic acid and its 3-oxo-analogue oleanonic acid, which was obtained from Pistacia terebinthus galls. The last one showed activity on the ear oedema induced by 12-deoxyphorbol-13-phenylacetate (DPP), the dermatitis induced by multiple applications of 12-O-tetradecanoyl-13-acetate (TPA) and the paw oedemas induced by bradykinin and phospholipase A2. The production of leukotriene B4 from rat peritoneal leukocytes was reduced by ol…

Blood PlateletsLeukotrienesLeukotriene B4medicine.drug_classNeutrophilsBradykininTetrazolium SaltsIn Vitro TechniquesLeukotriene B4Anti-inflammatorychemistry.chemical_compoundMiceStructure-Activity RelationshipPhospholipase A2medicineAnimalsEdemaHumansCyclooxygenase InhibitorsHypersensitivity DelayedEar ExternalOleanolic AcidOleanolic acidPeroxidasePharmacologyInflammationLeukotrienebiologyFootAnti-Inflammatory Agents Non-SteroidalBiological activityTriterpenesRatsThiazoleschemistryBiochemistryArachidonate 5-lipoxygenasePistaciabiology.proteinFemaleDrug Screening Assays AntitumorOxidation-ReductionEuropean journal of pharmacology
researchProduct

Near-infrared emitting fluorescent homobimetallic gold(I) complexes displaying promising in vitro and in vivo therapeutic properties

2021

International audience; Boron neutron capture therapy (BNCT) has the potential to specifically destroy tumor cells without damaging the tissues infiltrated by the tumor. BNCT is a binary treatment method based on the combination of two agents that have no effect when applied individually: 10B and thermal neutrons. Exclusively, the combination of both produces an effect, whose extent depends on the amount of 10B in the tumor but also on the organs at risk. It is not yet possible to determine the 10B concentration in a specific tissue using non-invasive methods. At present, it is only possible to measure the 10B concentration in blood and to estimate the boron concentration in tissues based o…

Boron Compoundsinorganic chemicalsCell SurvivalInfrared RaysAntineoplastic Agents01 natural sciencesMiceStructure-Activity Relationship03 medical and health sciencesOptical imagingCoordination ComplexesIn vivoDrug DiscoveryTumor Cells CulturedAza-bodipyAnimalsHumans[CHIM]Chemical SciencesNir fluorescenceComputingMilieux_MISCELLANEOUSCell ProliferationFluorescent Dyes030304 developmental biologyPharmacologyAza CompoundsMice Inbred BALB C0303 health sciencesDose-Response Relationship DrugMolecular Structure010405 organic chemistryChemistryOptical ImagingOrganic ChemistryNear-infrared spectroscopyNeoplasms ExperimentalGeneral MedicineFluorescenceIn vitro3. Good health0104 chemical sciencesBiophysicsGoldDrug Screening Assays AntitumorCancer cell lines
researchProduct

Catumaxomab: a bispecific trifunctional antibody.

2009

The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells. The trifunctional approach thus leads to unrestricted but specific killing of epithelial tumor cells by major histocompatibility complex without the need for preactivation or external costimulation. The tumor-associated antigen EpCAM is strongly expressed in carcinomas of various origins including colon, rectum, ovarian, gastric, esophagus, lung, pancreas, breast and head and neck. Expressio…

CD3CatumaxomabAntineoplastic AgentsMajor histocompatibility complexchemistry.chemical_compoundAntigenAntigens NeoplasmNeoplasmsAntibodies BispecificMedicineAnimalsHumansPharmacology (medical)PharmacologybiologyBispecific monoclonal antibodybusiness.industryDrug Administration RoutesModels ImmunologicalEpithelial cell adhesion moleculeGeneral MedicineTrifunctional antibodychemistrybiology.proteinCancer researchAntibodyDrug Screening Assays Antitumorbusinessmedicine.drugDrugs of today (Barcelona, Spain : 1998)
researchProduct

4,5,6,9-TETRAHYDROPYRROLO[2',3'-3,4]CYCLOEPTA[1,2-d]ISOSSAZOLE, PROCESS FOR THEIR PRODUCTION AND THEIR USES AS ANTITUMOR AGENTS

2016

The present invention concerns the synthesis of compounds bearing the PYRROLO[2',3'-3,4]CYCLOEPTA[1,2-d]ISOSSAZOLE structure, and their use for the treatment of pathologies having hyperproliferative features included those having neoplastic nature.

CYCLOEPTAISOSSAZOLE ANTITUMOR AGENTSSettore CHIM/08 - Chimica Farmaceutica
researchProduct